Study On The Aggregation Kinetics And Oral Bioavailability Of Solid Lipid Nanoparticles

In this paper, BSA and Cefodizime loading solid lipid nanoparticles wasprepared by W/O/W double emulsion-solvent evaporation technique. To resolve thestability problem of the SLNs and then better utilize them, the aggregation behavior ofthe BSA-SLN was investigatd to find out what factors would influence the stability ofthe SLN. The oral bioavailability of Cd-SLN was studied to find out if the SLN hasimproving effect on oral drug absorption of cefodizime.The mean size of the BSA-SLN was290nm, and the Entrapment Efficiency (EE)was84.62%. The aggregation behavior of the SLN was investigated to find out whatfactors would influence the stability of the SLN. Aggregation kinetics of theBSA-SLN exhibited reaction-limited (slow) and diffusion-limited (fast) regimes. Thecritical coagulation concentration (CCC) for SLNs containing0.0%,0.1%,0.5%,2.0%, and4.0%of Poloxamer188(F68) was416,328,519,607, and602mM,respectively, suggesting that the F68influence the aggregation behavior of the SLN.Zeta potential results suggest that the F68cannot affect the zeta potential of the SLNin sodium chloride solutions, so the proposed mechanism for F68influence stabilityof the SLN suggests a steric stabilization.The mean size of the Cd-SLN was220nm, and the Entrapment Efficiency (EE)was46.66%. The pharmacokinetics and absolute bioavailability of cefodizime weredetermined after intragastric administration administration to Wistar rats. The Cmax,Tmax, AUC0-T(n), AUC0-∞of the cefodizime was26.1μg/ml,4.0h,225.3μg h ml-1,228.6μg h ml-1, respectively. The absolute bioavailability of cefodizime was34.5%.The SLN led to the enhancement of AUC of cefodizime by around4.7fold incomparison with cefodizime solution. This result suggests that the drug loaded solidlipid nanopartieles can enhance the oral bioavailability of cefodizime.